These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 37813820)

  • 1. Novel therapeutic targets and emerging treatments for atherosclerotic cardiovascular disease.
    Zheng WC; Chan W; Dart A; Shaw JA
    Eur Heart J Cardiovasc Pharmacother; 2024 Jan; 10(1):53-67. PubMed ID: 37813820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the residual cardiovascular risk by specific anti-inflammatory interventions as a therapeutic strategy in atherosclerosis.
    Hafiane A; Daskalopoulou SS
    Pharmacol Res; 2022 Apr; 178():106157. PubMed ID: 35257900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
    Rosenblit PD
    Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current pharmacotherapies for atherosclerotic cardiovascular diseases.
    Park JG; Oh GT
    Arch Pharm Res; 2019 Mar; 42(3):206-223. PubMed ID: 30725249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interplay between hypercholesterolaemia and inflammation in atherosclerosis: Translating experimental targets into clinical practice.
    Tuñón J; Bäck M; Badimón L; Bochaton-Piallat ML; Cariou B; Daemen MJ; Egido J; Evans PC; Francis SE; Ketelhuth DF; Lutgens E; Matter CM; Monaco C; Steffens S; Stroes E; Vindis C; Weber C; Hoefer IE;
    Eur J Prev Cardiol; 2018 Jun; 25(9):948-955. PubMed ID: 29759006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Emerging Role of Inflammation in Cardiovascular Disease.
    Martinez BK; White CM
    Ann Pharmacother; 2018 Aug; 52(8):801-809. PubMed ID: 29557210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of Suppressing Inflammation in the Treatment of Atherosclerotic Cardiovascular Disease.
    Roman YM; Hernandez AV; White CM
    Ann Pharmacother; 2020 Oct; 54(10):1021-1029. PubMed ID: 32425120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolving Management of Low-Density Lipoprotein Cholesterol: A Personalized Approach to Preventing Atherosclerotic Cardiovascular Disease Across the Risk Continuum.
    Wilkinson MJ; Lepor NE; Michos ED
    J Am Heart Assoc; 2023 Jun; 12(11):e028892. PubMed ID: 37260036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing Dyslipidemia Management for the Prevention of Cardiovascular Disease: a Focus on Risk Assessment and Therapeutic Options.
    Berman AN; Blankstein R
    Curr Cardiol Rep; 2019 Aug; 21(9):110. PubMed ID: 31378838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inflammation and cardiovascular diseases: lessons from seminal clinical trials.
    Liberale L; Montecucco F; Schwarz L; Lüscher TF; Camici GG
    Cardiovasc Res; 2021 Jan; 117(2):411-422. PubMed ID: 32666079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis.
    Bertrand MJ; Tardif JC
    Expert Opin Emerg Drugs; 2017 Mar; 22(1):1-26. PubMed ID: 27927063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Residual Cardiovascular Risk at Low LDL: Remnants, Lipoprotein(a), and Inflammation.
    Hoogeveen RC; Ballantyne CM
    Clin Chem; 2021 Jan; 67(1):143-153. PubMed ID: 33257928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Antiatherosclerotic Therapies.
    Libby P; Everett BM
    Arterioscler Thromb Vasc Biol; 2019 Apr; 39(4):538-545. PubMed ID: 30816799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonstatin therapy to reduce low-density lipoprotein cholesterol and improve cardiovascular outcomes.
    Singh A; Cho LS
    Cleve Clin J Med; 2024 Jan; 91(1):53-63. PubMed ID: 38167398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Critical roles of inflammation in atherosclerosis.
    Moriya J
    J Cardiol; 2019 Jan; 73(1):22-27. PubMed ID: 29907363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Most important advances in preventive cardiology during this past decade: Viewpoint from the American Society for Preventive Cardiology.
    Wong ND; Toth PP; Amsterdam EA;
    Trends Cardiovasc Med; 2021 Jan; 31(1):49-56. PubMed ID: 31882264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Update on Inflammation in Atherosclerosis: How to Effectively Treat Residual Risk.
    Mohammadnia N; Opstal TSJ; El Messaoudi S; Bax WA; Cornel JH
    Clin Ther; 2023 Nov; 45(11):1055-1059. PubMed ID: 37716836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Moving beyond JUPITER: will inhibiting inflammation reduce vascular event rates?
    Ridker PM
    Curr Atheroscler Rep; 2013 Jan; 15(1):295. PubMed ID: 23225175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS).
    Ridker PM; Libby P; MacFadyen JG; Thuren T; Ballantyne C; Fonseca F; Koenig W; Shimokawa H; Everett BM; Glynn RJ
    Eur Heart J; 2018 Oct; 39(38):3499-3507. PubMed ID: 30165610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.